104 related articles for article (PubMed ID: 9750526)
1. [A study on androgen deprivation therapy prior to radical prostatectomy with special reference to the tumor volume].
Hachiya T; Nogaki J; Ishida H; Okada K
Nihon Rinsho; 1998 Aug; 56(8):2157-61. PubMed ID: 9750526
[TBL] [Abstract][Full Text] [Related]
2. [Neoadjuvant androgen deprivation preceding to radical prostatectomy--its role in short-term and long-term outcomes].
Homma Y
Nihon Rinsho; 1998 Aug; 56(8):2162-6. PubMed ID: 9750527
[TBL] [Abstract][Full Text] [Related]
3. [Radiation therapy with neoadjuvant hormonal therapy for prostate cancer confined to pelvis].
Furuya Y; Akakura K; Ito H
Nihon Rinsho; 1998 Aug; 56(8):2181-4. PubMed ID: 9750531
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
Garzotto M; Wajsman Z
J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
[TBL] [Abstract][Full Text] [Related]
7. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
8. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
9. [Application and limitation of neoadjuvant hormonal therapy for prostate cancer].
Demura T; Shinohara N; Nonomura K; Koyanagi T
Nihon Rinsho; 1998 Aug; 56(8):2150-6. PubMed ID: 9750525
[TBL] [Abstract][Full Text] [Related]
10. [Advanced prostatic carcinoma--which hormone therapy when?].
Studer UE
Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
[No Abstract] [Full Text] [Related]
11. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant hormone therapy with casodex in a dose 150 mg prior to radical prostatectomy in patients with prostatic cancer].
Rusakov IG; Petrov SB; Alekseev BIa; Veliev EI
Urologiia; 2004; (4):15-9. PubMed ID: 15457946
[No Abstract] [Full Text] [Related]
14. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
Boccon-Gibod L
Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
[No Abstract] [Full Text] [Related]
16. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
17. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T
Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
19. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
20. [Treatment results of radical prostatectomy in clinical stage B and C prostate cancer: comparison of the neoadjuvant therapy group versus the surgery group; retrospective analysis of 80 cases].
Ogura Y; Sakata Y; Wakita T; Hayashi N; Hioki T; Sugimura Y
Hinyokika Kiyo; 2003 Sep; 49(9):515-20. PubMed ID: 14598688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
